Overview

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway

Status:
Not yet recruiting

Trial end date:
2026-07-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS, MAPK pathways.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Treatments:

Adagrasib